Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune… Read more
Market Cap & Net Worth: Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. (OTCQB:RAPH) has a market capitalization of $19.63 Million ($19.63 Million) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #27895 globally and #9321 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Raphael Pharmaceutical Inc.'s stock price $1.00 by its total outstanding shares 19626418 (19.63 Million).
Raphael Pharmaceutical Inc. Market Cap History: 2023 to 2025
Raphael Pharmaceutical Inc.'s market capitalization history from 2023 to 2025. Data shows change from $19.63 Million to $19.63 Million (-29.60% CAGR).
Raphael Pharmaceutical Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Raphael Pharmaceutical Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RAPH by Market Capitalization
Companies near Raphael Pharmaceutical Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Raphael Pharmaceutical Inc. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Raphael Pharmaceutical Inc. Historical Marketcap From 2023 to 2025
Between 2023 and today, Raphael Pharmaceutical Inc.'s market cap moved from $19.63 Million to $ 19.63 Million, with a yearly change of -29.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $19.63 Million | +284.62% |
| 2024 | $5.10 Million | -74.00% |
| 2023 | $19.63 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Raphael Pharmaceutical Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.63 Million USD |
| MoneyControl | $19.63 Million USD |
| MarketWatch | $19.63 Million USD |
| marketcap.company | $19.63 Million USD |
| Reuters | $19.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.